Captopril (Chemmart) is a medicine containing the active ingredient(s) captopril. On this page you will find out more about Captopril (Chemmart), including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: captopril
Pack size information
Please select the pack size from the options directly below to view information on the medicine.
Information for medicine and pack size:
Captopril (Chemmart) 25 mg uncoated tablet, 90
Consumer Medicine Information leaflet:
This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.
What this medicine is for
HYPERTENSION: Captopril is indicated for the treatment of hypertension. Consideration should be given to the risk of neutropenia/ agranulocytosis when using captopril (see PRECAUTIONS). Captopril is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of captopril and thiazides are approximately additive. MYOCARDIAL INFARCTION - Captopril is indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction, manifested as an ejection fraction less than or equal to 40% and to reduce the incidence of overt heart failure, and subsequent hospitalisation for congestive heart failure in these patients. The efficacy data for the use of captopril following myocardial infarction are strongest for initiation of therapy beyond 3 days post-infarct. HEART FAILURE - Captopril is indicated for the treatment of heart failure. In symptomatic patients it is recommended that captopril be administered together with a diuretic. DIABETIC NEPHROPATHY - Captopril is indicated for the treatment of diabetic nephropathy (proteinuria > 500mg/day) in patients with Type 1 insulin-dependent diabetes mellitus. In these patients captopril reduces the progression of renal disease and reduces associated clinical sequelae (dialysis, renal transplantation and death).
Table of characteristics
|Visual appearance||White, square, biconvex tablet. Quadrisect on one side, other side engreaved APO over 25.|
|Dosage Form||Tablet, uncoated|
|Route of administration||Oral|
90 tablets: Prescription Only Medicine, or Prescription Animal Remedy
There is one type of pack available.
Pack type 1
|Storage temperature||Store below 25 degrees Celsius|
|Storage conditions||Protect from Moisture|
|Life time||2 Years|
We were unable to verify that this medicine is available on the PBS (Pharmaceutical Benefits Scheme). Please consult your pharmacist if you need further information
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.